Why the study?
Does cardiac-directed adenylyl cyclase type VI expression improve heart function in a murine model of cardiomyopathy?
Does cardiac-directed adenylyl cyclase type VI expression improve heart function in a murine model of cardiomyopathy?
Increasing myocardial adenylyl cyclase type VI content in a murine model of cardiomyopathy restores cAMP-generating capacity and improves cardiac function.
Answers are grounded in this paper and cite their sources.
Supports further AC VI testing in cardiomyopathy models; should not change clinical practice.
BACKGROUND: We tested the hypothesis that increased cardiac myocyte adenylyl cyclase (AC) content increases cardiac function and response to catecholamines in cardiomyopathy. METHODS AND RESULTS: Transgenic mice with cardiac-directed expression of AC type VI (ACVI) were crossbred with mice with cardiomyopathy induced by cardiac-directed Gq expression. Gq mice had dilated left ventricles, reduced heart function, decreased cardiac responsiveness to catecholamine stimulation, and impaired beta-adrenergic receptor (betaAR)-dependent and AC-dependent cAMP production. Gq/AC mice showed improved basal cardiac function in vivo (P=0.01) and ex vivo (P<0.0005). When stimulated through the betaAR, cardiac responsiveness was increased (P=0.02), and cardiac myocytes showed increased cAMP production in response to isoproterenol (P=0.03) and forskolin (P<0.0001). CONCLUSIONS: Increasing myocardial ACVI content in cardiomyopathy restores cAMP-generating capacity and improves cardiac function and responsiveness to betaAR stimulation.
No takes yet. Share an insight, caveat, or question.
Roth et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: